Brief: Decibel Therapeutics Reports Positive Data From Interim Analysis Of Ongoing Phase 1B Clinical Trial Of Db-020 In Patients Receiving Cisplatin Chemotherapy

Decibel Therapeutics

28/06/2022 12:29

June 28 (Reuters) - Decibel Therapeutics Inc  DBTX.O :
    * DECIBEL THERAPEUTICS REPORTS POSITIVE DATA FROM INTERIM
ANALYSIS
OF ONGOING PHASE 1B CLINICAL TRIAL OF DB-020 IN PATIENTS
RECEIVING CISPLATIN CHEMOTHERAPY
    * DECIBEL THERAPEUTICS INC - 87% OF PATIENTS WHO EXPERIENCED
OTOTOXICITY IN THEIR PLACEBO-TREATED EAR WERE PROTECTED FROM
OTOTOXICITY IN THEIR DB-020-TREATED EAR
    * DECIBEL-DATA SUPPORT CONTINUED DEVELOPMENT OF DB-020 AS
POTENTIAL THERAPY TO PROTECT AGAINST HEARING LOSS IN PATIENTS
RECEIVING CISPLATIN CHEMOTHERAPY
    * DECIBEL THERAPEUTICS INC - DATA FROM INTERIM ANALYSIS
DEMONSTRATED THAT DB-020 WAS WELL TOLERATED, WITH ADVERSE EVENTS
GENERALLY MILD TO MODERATE
    * DECIBEL THERAPEUTICS INC - DB-020, ADMINISTERED PRIOR TO
CISPLATIN, HAD NO APPARENT EFFECT ON SYSTEMIC CISPLATIN LEVELS

Source text for Eikon:  ID:nGNX9DGBbz 
Further company coverage:  DBTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))